Hepatitis B Virus (e.g., Hepatitis B Surface Antigen (hbsag), Pre-s Region, Hepatitis B Core Antigen (hbcag), Hepatitis B E-antigen, Dane Particle, Etc.) Patents (Class 424/227.1)
  • Patent number: 10967044
    Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: April 6, 2021
    Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
  • Patent number: 10925925
    Abstract: An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 23, 2021
    Assignee: MYR GMBH
    Inventor: Alexander Alexandrov
  • Patent number: 10898567
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: January 26, 2021
    Assignee: ISA PHARMACEUTICALS B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • Patent number: 10376576
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and/or prevention of a Hepatitis B viral infection and/or an Hepatitis B related disease or condition.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: August 13, 2019
    Assignee: ISA Pharmaceuticals B.V.
    Inventors: Wilhelmus Johannes Theodorus Alexander Krebber, Johan Herman Kessler, Cornelis Joseph Maria Melief, Kitty Michelle Corinne Kwappenberg
  • Patent number: 10357559
    Abstract: Vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided. Vaccines comprising the formulations are useful, for example, to protect against, inhibit or alleviate a disease or infection, such as related to anthrax infection.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: July 23, 2019
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Jee Look, Christian Fernando Ruiz, Aaron Paul Miles, Richard William Welch
  • Patent number: 10251841
    Abstract: Provided herein are polymeric particles and compounds and processes that can be used to prepare polymer-based particles and methods of using those particles to localize or concentrate a subsequently delivered agent to an in vivo site.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 9, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Mark W. Grinstaff, Aaron H. Colby, Yolonda Colson
  • Patent number: 10188734
    Abstract: The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: January 29, 2019
    Assignee: MERIAL, INC.
    Inventor: Noel Yves Henri Jean Genin
  • Patent number: 9989520
    Abstract: A human hepatoma cell line is HLCZ01 cell line which has been deposited in the China Center for Type Culture Collection (CCTCC), and having Accession (deposit) No. is CCTCC NO: C201309. The human hepatoma cell line HLCZ01 is used as a cell model supporting said hepatitis viruses infection and is used to establish an animal model for supporting virus infection, wherein said human hepatoma cell line HLCZ01 is also used for preparation, screening and evaluating anti-hepatitis virus drugs, anti-tumor drugs, and used for manufacturing artificial liver.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: June 5, 2018
    Assignee: HUNAN UNIVERSITY
    Inventors: Haizhen Zhu, Chaohui Zuo, Xiaohong Wang, Darong Yang, Nianli Liu
  • Patent number: 9777043
    Abstract: The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation).
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 3, 2017
    Assignee: Variation Biotechnologies Inc.
    Inventors: David E. Anderson, Anne-Catherine Fluckiger
  • Patent number: 9623094
    Abstract: The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: April 18, 2017
    Assignee: Advanced BioNutrition Corporation
    Inventors: Moti Harel, Brian Carpenter
  • Patent number: 9610354
    Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: April 4, 2017
    Assignee: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
    Inventors: Takashi Okada, Shin'ichi Takeda, Hiromi Kinoh
  • Patent number: 9339537
    Abstract: Provided are an agent for inhibition of cancer development, an agent for improvement of antibody productivity, and an agent for treatment of hepatitis. The agents have been completed by finding that cancer development is inhibited in a healthy subject by administering NK cells, and antibody productivity is improved by administering NK cells and a vaccine to a patient.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: May 17, 2016
    Assignees: Cellex Corporation
    Inventors: Junichi Masuyama, Sanehiko Fujita
  • Patent number: 9297033
    Abstract: Methods for the rapid detection of the presence or absence of a SNP in a target nucleic acid in a sample are described. The methods can include performing an amplifying step, a hybridizing step utilizing a SNP specific hydrolysis probe including a hairpin structure toward the 3? end, and a detecting step. Furthermore, SNP specific hydrolysis probe including a hairpin structure toward the 3? end, along with kits are provided that are designed for the detection of a SNP in a target nucleic acid.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: March 29, 2016
    Assignee: ROCHE MOLECULAR SYSTEMS, INC.
    Inventor: Rochak Mehta
  • Patent number: 9066895
    Abstract: The invention relates to a method for loading and storing a vaccine composition, containing the antigen adsorbed on the aluminum adjuvant which (a) comprises (i) loading the composition into a container; and (ii) closing the container with a device in particular acting as a stopper, the surface of the device getting into contact with the composition being coated with a fluoropolymer such as Teflon™; and/or (b) loading the composition into a container wherein the inner surface of which is coated with polymerized silicone. The use of fluoropolymer or polymerized silicone optimizes the adsorbed antigen stability upon storage. In a particular embodiment, the antigen is the hepatitis B surface antigen and the aluminum adjuvant is aluminum oxy hydroxide.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: June 30, 2015
    Assignee: Sanofi Pasteur SA
    Inventors: Isabelle Chacornac, Nabila Ikhelef-Gribi, Frédéric Ronzon, Julien Tirefort, Sandrine Lentsch Graf
  • Publication number: 20150132258
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventor: George D. Hartman
  • Patent number: 9023319
    Abstract: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 5, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Michael Decker
  • Publication number: 20150118264
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: April 30, 2015
    Applicant: CureVac GMBH
    Inventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Patent number: 9017695
    Abstract: Chimeric therapeutics are disclosed that include a modified viral core protein comprising at least one mutation or modification in an immunogenic epitope and a therapeutic agent. The therapeutic agent may be associated with the modified viral core protein and may be a nucleic acid, a protein, or a small molecule. Also disclosed are particles and compositions that include the disclosed chimeric therapeutics.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: April 28, 2015
    Assignee: Biomed Realty, L.P.
    Inventors: Miguel de los Rios, Stephanie de los Rios
  • Publication number: 20150071879
    Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).
    Type: Application
    Filed: October 17, 2014
    Publication date: March 12, 2015
    Inventor: Jan JEZEK
  • Patent number: 8956812
    Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: February 17, 2015
    Assignee: Bharat Biotech International Limited
    Inventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
  • Patent number: 8945590
    Abstract: This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: February 3, 2015
    Assignee: Juvaris BioTherapeutics, Inc.
    Inventors: Jeffery Fairman, Marla Lay Vaughn
  • Publication number: 20150010595
    Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
    Type: Application
    Filed: June 11, 2014
    Publication date: January 8, 2015
    Applicant: Valneva Austria GmbH
    Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
  • Publication number: 20150004194
    Abstract: Provided herein is a vaccine that combines a vaccine facilitator and a DNA construct encoding an antigen to elicit antigen-specific antibody responses, wherein the vaccine facilitator is a Na/K pump inhibitor. Cellular entry of the DNA is accelerated as compared to other vaccines that do not contain the vaccine facilitator.
    Type: Application
    Filed: November 10, 2011
    Publication date: January 1, 2015
    Inventors: Bin Wang, Shuang Geng
  • Publication number: 20140356408
    Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Inventor: Victor Bronshtein
  • Publication number: 20140350483
    Abstract: A syringe containing a compressible porous matrix, which compressible porous matrix has in it a pharmaceutical in a soluble glass, Methods of producing and using the syringe, and compressible porous matrix inserts for insertion into a syringe barrel are also provided.
    Type: Application
    Filed: January 28, 2013
    Publication date: November 27, 2014
    Inventor: Bruce Roser
  • Patent number: 8895237
    Abstract: This invention relates to a HB vaccine enhancing protein, its gene, gene engineering method for expressing this protein, and the application of this method. The cDNA of this protein, which is screened out from human liver cDNA library, is sequenced and then cloned into prokaryotic or eukaryotic (animal or plant) cell for expression of protein coded by the cDNA (for example, cloning into prokaryotic expression carrier and expression in E. coli) and purification of the protein. The protein obtained, when used with HB vaccine, can significantly increase the effect of the vaccine, the immune power of HBV carrier, and the titer of antibody. The protein can be used as an adjutant to HB vaccine.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: November 25, 2014
    Assignee: Fudan University
    Inventors: Naishuo Zhu, Huaqing Li, Min Yang
  • Publication number: 20140341974
    Abstract: A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.
    Type: Application
    Filed: March 17, 2014
    Publication date: November 20, 2014
    Inventors: Aryo Sorayya, Mitra Mosharraf, Rajiv Nayar
  • Patent number: 8883745
    Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: November 11, 2014
    Assignees: New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New York
    Inventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
  • Patent number: 8883169
    Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: November 11, 2014
    Assignee: Chrontech Pharma AB
    Inventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
  • Publication number: 20140328876
    Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 6, 2014
    Inventor: Maura Ellen Campbell
  • Publication number: 20140322272
    Abstract: The present invention provides immunogenic compositions comprising one or more antigens and an adjuvant for use in cutaneous immunisation wherein said adjuvant is an immunologically active saponin.
    Type: Application
    Filed: November 19, 2012
    Publication date: October 30, 2014
    Inventors: Nathalie Marie-Josephe Garcon-Johnson, Marcelle Paulette Van Mechelen, Martin Plante
  • Publication number: 20140322271
    Abstract: The present invention provides immunogenic compositions comprising one or more antigens and an adjuvant for use in cutaneous immunisation wherein said adjuvant is a TLR-5 agonist.
    Type: Application
    Filed: November 19, 2012
    Publication date: October 30, 2014
    Inventors: Nathalie Marie-Josephe Garcon-Johnson, Marcelle Paulette Van Mechelen, Martin Plante
  • Publication number: 20140314739
    Abstract: The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine. Also provided is a single-dose vaccine composition comprising inulin particles, an antigen and, optionally, an antigen-binding carrier material, and methods and uses of the vaccine.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 23, 2014
    Applicant: Vaxine Pty Ltd.
    Inventor: Nikolai Petrovsky
  • Publication number: 20140287043
    Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.
    Type: Application
    Filed: April 23, 2012
    Publication date: September 25, 2014
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Fiorenzo Omenetto
  • Publication number: 20140255446
    Abstract: Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 ?g per human dose.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Crucell Holland B.V.
    Inventor: Jan Theunis POOLMAN
  • Patent number: 8802111
    Abstract: When preparing HBsAg for use in a combination vaccine, it us known to add a non-ionic detergent after the HBsAg has been purified. Adding detergents after purification of HBsAg is not optimal, however, as it requires a separate processing step during manufacture. Thus the invention uses them during HBsAg purification.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: August 12, 2014
    Assignee: Novartis Vaccines and Diagnostics, SRL
    Inventor: Mario Contorni
  • Publication number: 20140220076
    Abstract: The invention relates to vaccines that comprise antigens and an adjuvant, and to the use of the adjuvant, wherein the adjuvant is selected from a recombinant mistletoe lectin.
    Type: Application
    Filed: June 27, 2012
    Publication date: August 7, 2014
    Applicant: Cytavis Biopharma GmbH
    Inventors: Klaus Witthohn, Hans Lentzen
  • Publication number: 20140219954
    Abstract: The present invention relates to methods for making a stabilized powder formulation for inhalation comprising a macromolecule in lyophilized form, a crystalline carrier material, and magnesium stearate.
    Type: Application
    Filed: March 17, 2014
    Publication date: August 7, 2014
    Inventor: Rudi Mueller-Walz
  • Patent number: 8790658
    Abstract: Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to mammals and methods for eliciting an immune response in mammals by administering the compositions.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 29, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Sandrine Cigarini, Kevin Harper, Manvi Hasija
  • Patent number: 8784837
    Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: July 22, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
  • Publication number: 20140186292
    Abstract: Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Providence Health & Services - Oregon
    Inventor: Hong-Ming Hu
  • Patent number: 8765143
    Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: July 1, 2014
    Assignee: Universite Francois Rabelais de Tours
    Inventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient
  • Publication number: 20140178431
    Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.
    Type: Application
    Filed: November 8, 2013
    Publication date: June 26, 2014
    Applicant: North-West University
    Inventors: Anne Grobler, Abraham Frederik Kotze
  • Publication number: 20140161826
    Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.
    Type: Application
    Filed: April 5, 2012
    Publication date: June 12, 2014
    Inventor: Antonello Pessi
  • Publication number: 20140127263
    Abstract: The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 8, 2014
    Applicant: OmniGen Research, L.L.C.
    Inventors: Neil E. Forsberg, Steven B. Puntenney
  • Publication number: 20140112951
    Abstract: Disclosed and claimed is a method of non-invasive immunization in an animal and/or a method of inducing a systemic immune response or systemic therapeutic response to a gene product. The skin of the animal is contacted with a non-replicative vector chosen from the group of bacterium, virus, and fungus, wherein the vector comprises and expresses a nucleic acid molecule encoding the gene product, in an amount effective to induce the response.
    Type: Application
    Filed: August 7, 2013
    Publication date: April 24, 2014
    Applicant: UAB RESEARCH FOUNDATION
    Inventors: De-Chu C. Tang, Zhongkai Shi, Kent Rigby van Kampen
  • Publication number: 20140112954
    Abstract: The present invention discloses a method for preparing HBV Vaccine comprising aluminum adjuvant, which belongs to biological technology field. The method, which is characterized in that aluminum adjuvant Al(OH)3 is produced by an on-line reaction, comprises mixing PBS buffer solution and potassium aluminum sulfate (KAl(SO4)2) solution with hepatitis B surface antigen stock solution, adding sodium hydroxide (NaOH) solution into the mixed solution, so that the adjuvant is continuously produced and hepatitis B surface antigens are continuously coated and absorbed simultaneously. The process is called “in-situ adsorption”.
    Type: Application
    Filed: April 18, 2012
    Publication date: April 24, 2014
    Applicant: DALIAN HISSEN BIO-PHARM CO., LTD.
    Inventors: Guixing Li, Ping Zhang, Haichun Zhang, Xinting Chen, Xiaoyu Li, Juan Zhang, Caixia Su
  • Publication number: 20140099339
    Abstract: The present invention relates to a combination of 2 or more S pneumoniae proteins, their manufacture and use in medicine as a vaccine. Such combinations are particularly useful for the protection of infants and elderly against streptococcal infection.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Hermand, Craig A. J. Laferriere, Yves Lobet, Jan Poolman
  • Patent number: 8679762
    Abstract: [PROBLEMS] To provide a probe useful in the detection of HBV or HBs antigen by which an escape mutant of hepatitis B virus (HBV) possibly occurring in a specimen can be detected; and a method of using the same. [MEANS FOR SOLVING PROBLEMS] A probe capable of recognizing an epitope located on a peptide comprising the amino acid sequence of SEQ ID NO:1; and a method of detecting hepatitis B virus or hepatitis B virus s antigen by using this probe.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: March 25, 2014
    Assignee: Advanced Life Science Institute, Inc.
    Inventors: Noboru Maki, Yasuyuki Fukuda, Tatsuji Kimura, Yoko Oda, Chiharu Ohue, Osamu Kusano
  • Patent number: 8673311
    Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: March 18, 2014
    Assignee: Royal Holloway and Bedford New College
    Inventors: Simon Michael Cutting, Hong Anh Huynh